Oncologist. The. Clinical Pharmacology: Concise Drug Reviews. Imatinib INTRODUCTION MECHANISM OF ACTION CLINICAL USE
|
|
- Sophia Stewart
- 5 years ago
- Views:
Transcription
1 The Oncologist Clinical Pharmacology: Concise Drug Reviews Imatinib CHRISTINE E. DE KOGEL, a JAN H. M. SCHELLENS a,b a Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands; b Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article. LEARNING OBJECTIVES After completing this course, the reader will be able to: 1. Identify the current indications for imatinib. 2. Describe the pharmacokinetics of imatinib. 3. Discuss the mechanisms involved in imatinib resistance. CME INTRODUCTION Access and take the CME test online and receive 1 AMA PRA Category 1 Credit at CME.TheOncologist.com Imatinib (Fig. 1) is currently registered in adults for two indications: (a) monotherapy in chronic myeloid leukemia (CML) and (b) monotherapy in c-kit (CD117)-positive unresectable or metastatic gastrointestinal stromal tumors (GISTs) [1, 2]. Clinical trials showed that the activity of imatinib in other malignancies, such as small cell lung cancer, acute myeloid leukemia, and prostate cancer, is negligible. In combination with hydroxyurea, imatinib has activity in glioblastoma multiforme [3]. In children, the use of imatinib mesylate is registered for patients with Philadelphia chromosome positive (Ph ) chronic CML that is resistant to interferon- therapy or recurrent after bone marrow transplantation. both indications. In GIST, most patients are started on a single dose of 400 mg daily, with dose escalation to a single dose of 600 mg daily or 400 mg twice daily if disease progression occurs during treatment. GIST patients with a mutation in exon 9 are commonly started on a single dose of 600 mg daily, because of a longer progression-free survival time in clinical trials for this dose. Patients with CML in the chronic phase are started on a single dose of 400 mg daily as well. CML patients in the acceleration phase or in blast crisis are started on 600 mg daily as a single dose. Dose escalations to a maximum of 400 mg twice daily are started if progression occurs. In children with chronic phase Ph CML, the standard starting dose is 260 mg/m 2 per day, preferentially administered as a single dose. CLINICAL USE Imatinib is available as oral tablets of 100 and 400 mg strength. The recommended dose ranges between 400 and 800 mg daily in MECHANISM OF ACTION Imatinib is a tyrosine kinase inhibitor. Binding studies are compatible with competitive inhibition of ATP binding [1, 4]. It in- Correspondence: Jan H.M. Schellens, M.D., Ph.D., Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Telephone: ; Fax: ; jhm@nki.nl Received May 14, 2007; accepted for publication October 22, AlphaMed Press /2007/$30.00/0 doi: /theoncologist The Oncologist 2007;12:
2 de Kogel, Schellens 1391 SUMMARY TABLE Generic name(s) Imatinib mesylate Commercial name(s) Gleevec /Glivec Molecular weight g/mol Mechanism of action Inhibition of tyrosine kinase activity by competitive inhibition of ATP binding to Bcr-Abl, CD117 (c-kit), and the PDGF receptor Cell-cycle specificity G 1 phase [13] Route of Oral; bioavailability nearly complete, unaffected by food administration Protein binding (%) 95% Metabolism Metabolism to the active metabolite N-demethylated piperazine by the CYP3A4 isoenzyme; further metabolized by N-oxidation of the 4-nitrogen of the piperazine and N-oxidation of the pyridine nitrogen Elimination Terminal half-life Main toxicities Pharmacogenetics Resistance Unique features Main drug interactions Biotransformation approximately 75%; renal elimination, 13%; fecal elimination (via bile), 68%, of which, parent drug, 20% 19 hours (active parent compound) (range, hours) 40 h (active metabolite) (range h) Mild nausea, vomiting, edema, muscle cramps, liver dysfunction, and bone marrow toxicity No known effect of CYP3A4 polymorphisms on pharmacokinetics; the relevance of polymorphisms in ABCB1 and ABCG2 is being studied Will develop as a result of overexpression of the tyrosine kinase, genomic amplification of the kinase, clonal selection of resistant cells, and resistanceinducing mutations; important mutations in CML include E255K/V, Y253F/H (Ploop), T315I (binding pocket) and M351T (activation loop). Important mutations in GIST include exon 13 V654A and exon 14 T670I (binding pocket), and exon 17 C809G, D816H, D820A/E/G, N822K/H, and Y823D (activation loop); pharmacokinetic resistance may also play a role, but needs clinical confirmation Practical because of oral therapy CYP3A4 inhibitors such as ketoconazole and erythromycin and CYP3A4 inducers such as rifampicin and the herb St. John s Wort; CYP3A4 substrates such as cyclosporine and simvastatin Abbreviations: ABC, ATP-binding cassette; Bcr-Abl, breakpoint cluster region/abelson; CML, chronic myelogenous leukemia; CYP3A4, cytochrome P450 3A4 isoenzyme; GIST, gastrointestinal stromal tumor; PDGF, platelet-derived growth factor. hibits the Abelson (Abl) tyrosine kinase with high selectivity. Concentrations above 0.3 mol/l were sufficient to inhibit Abl in in vitro studies. In in vivo studies, concentrations 1 M were needed for normalization of hematological parameters [5]. It also inhibits CD117 and platelet-derived growth factor (PDGF)- and PDGF- at concentrations of approximately 0.5 mol/l in vitro [1, 2]. These tyrosine kinases play a significant role in the growth and proliferation of malignant cells in CML, GIST, and the rare disease dermatofibrosarcoma protuberans. BIOANALYSIS Figure 1. Chemical structure of imatinib mesylate. Bioanalysis of imatinib and its metabolites can be performed by liquid chromatography mass spectrometry or liquid chromatography tandem mass spectrometry [6].
3 1392 Imatinib PHARMACOKINETICS Absorption After oral intake, imatinib is rapidly absorbed from the gut, because of its rapid dissolution at acidic ph [5]. Imatinib should be taken with a meal and water to reduce gastrointestinal side effects. However, a high fat meal can prolong the uptake and therefore the time to reach a maximum plasma concentration (t max ). Under normal conditions, the maximal plasma concentration of approximately 1.9 g/ml is reached after 2 4 hours [5]. After repeated administration of 400 mg of imatinib per day, the mean plasma concentration in steady state is 1 mol/l after 24 hours. Absolute bioavailability is estimated to be almost complete, but can be significantly lower in some cases as a result of limited absorption. Bioavailability is unaffected by food [5]. Protein Binding Imatinib is highly protein bound. It binds mostly to albumin. Protein binding is approximately 95% [5]. Imatinib also binds to 1-acid-glycoprotein in vitro and in vivo. 1- Acid-glycoprotein levels are elevated in patients with CML and GIST. However, it is thought that at clinically relevant doses, 1-acid-glycoprotein binding does not influence the activity of imatinib. Metabolism Imatinib is metabolized by the cytochrome P450 (CYP) isoenzymes in the gut wall and liver. The metabolism is mainly mediated by CYP3A4 and CYP3A5, but other CYP isoenzymes such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19 also play minor roles. The main metabolite is the N-demethylated piperazine derivate (Fig. 2). Based on in vitro data, this metabolite has potency comparable to that of the parent compound [5]. The exposure measured as a percentage of the area under the concentration time curve in plasma of the N-demethylated piperazine derivate is approximately 10% 15% of that of imatinib. In addition, imatinib and its N-demethylated piperazine derivate are N-oxidized in the liver [5]. Elimination On average, 75% of the dose of imatinib undergoes biotransformation. Imatinib has a terminal half-life of 19 hours (range, hours), while its main metabolite has a terminal half-life of 40 hours (range, hours) [5]. Excretion takes place mainly via the bile, 68% as metabolites and 20% as parent compound. Renal excretion is low, as only 13% of the metabolites and 5% of the parent compound are excreted via the kidneys [5]. Figure 2. Chemical structure of the N-demethylated piperazine derivate. Drug Interactions The metabolism of imatinib is largely dependent on CYP3A4. Therefore, caution should be undertaken when patients are treated with inducers and/or inhibitors of CYP3A4 during imatinib therapy. Inhibitors, such as ketoconazole and erythromycin, led to higher plasma concentrations of imatinib in clinical trials [5]. Inducers, such as rifampicin and the herb St. John s Wort, can lower the terminal half-life of imatinib twoto fourfold. This is relevant because patients could fail to respond to treatment as a result of the greater clearance of the drug [5]. As imatinib itself is also an inhibitor of CYP3A4, competitive inhibition of certain drugs, such as simvastatin and cyclosporine, can occur. This can increase drug exposure to both compounds [5]. Alterations with Disease or Age According to clinical trials, age has no significant influence on the pharmacokinetics of imatinib, although the volume of distribution increases with age [5]. Pharmacokinetic parameters in pediatric patients were comparable to those found in adults. Information on the effect of diminished liver or kidney function on the pharmacokinetics of imatinib is limited. Although metabolism is highly dependent on liver enzymes, patients with liver dysfunction seem to tolerate the standard dosage of imatinib well [5]. Although renal clearance of imatinib is low, it was shown in a clinical trial that imatinib clearance is slower in patients with renal dysfunction (creatinine clearance, 40 ml/minute). The implications of this slower clearance for clinical safety are as yet unknown [5]. PHARMACOGENETICS As metabolism of imatinib occurs mainly via the CYP isoenzymes, polymorphisms in these isoenzymes might in-
4 de Kogel, Schellens 1393 fluence the pharmacokinetic parameters and thus drug exposure in vivo. A study by Gardner et al. [7] in patients with GIST and in human embryo kidney cells showed no significant effect of polymorphisms in CYP3A4 and CYP3A5 on the pharmacokinetic parameters of imatinib. This is probably a result of the already large variability in the activity and expression of CYP3A4 and CYP3A5 in cancer patients and the relatively low allelic frequencies. Polymorphisms in CYP2C9, CYP2C19, and CYP2D6 were also of no significant relevance in explaining the large interpatient variability in the pharmacokinetics of imatinib. However, an oral clearance higher than the mean value was shown to be more common in patients with wild-type CYP2D6 alleles as compared with patients with a CYP2D6*4 polymorphism [7]. Excretion of imatinib occurs mainly via the bile. It was shown that imatinib is a substrate for the ATP-binding cassette (ABC) transporters ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein), and these biliary pumps probably mediate substantial elimination of imatinib. Further investigation on the influence of ABCB1 and ABCG2 polymorphisms on imatinib pharmacokinetics is ongoing [8]. DRUG RESISTANCE Although imatinib is an effective drug, resistance develops over time in almost all patients. In CML this drug resistance has been most elaborately studied. Resistance can be caused by several different mechanisms. First, in some patients, a two- to tenfold genomic amplification of the breakpoint cluster region Abelson gene (bcr-abl) is found. Secondly, in some patients, overexpression of bcr-abl is observed [9]. In these first two groups of patients, dose escalations might at least temporarily overcome resistance [2]. Finally, in CML patients, various mutations have been found in the bcr-abl gene. These mutations reduce the affinity of imatinib for the tyrosine kinase and therefore induce resistance. [2, 9] The most frequently seen mutations are E255K, E255V, Y253F, and Y253H in the P-loop of the Bcr-Abl protein and mutations at T315, M351, and E355. Resistance mutations have two main effects: they impair binding of imatinib to Bcr-Abl and they induce stable activation of Bcr-Abl that is insensitive to imatinib [9, 10]. In patients with GISTs, resistance is common as well. In rare cases, overexpression of CD117 or gene amplification has been found. Dose escalations might prove effective in this group of patients. However, this type of resistance seems of minor importance in GIST. Secondary mutations are the primary cause of resistance in GIST patients. Secondary mutations occur commonly in patients with primary exon 11 mutations and are rare in other CD117 mutations. Two separate types of mutations occur: (a) mutations that induce structural changes to the ATP-binding pocket and (b) mutations to the activation loop at exon 17, that activate CD117 in an imatinib-insensitive manor. In the first group, mutations V654A at exon 13 and T670I at exon 14 are most common. In the second group, several mutations have been found, including C809G, D816H, D820A/E/G, N822K/H, and Y823D [11]. A small group of GIST patients show mutations in PDGF receptor (PDGFR)- instead of CD117 activation. These patients show primary resistance if a D842V mutation at exon 18 is found. This mutation can also cause secondary resistance in patients with another primary PDGFR- mutation, such as V561D at exon 12 [11]. Besides these specific causes of resistance to imatinib, it is thought that pharmacokinetic resistance also may play a role. Several possible mechanisms have been described including (a) upregulation of liver enzymes, causing increased clearance of imatinib and (b) upregulation of drug transporters such as ABCB1 and ABCG2. Clinical studies are warranted to determine whether these supposed mechanisms play a relevant role in dosing of patients, because dose escalation should be effective in these forms of resistance [9 11]. PHARMACODYNAMICS The pharmacokinetic pharmacodynamic relationships of imatinib have not been extensively studied. However, there seems to be a relationship between dose and likelihood of tumor response. In CML, patients treated at a dose 400 mg/day showed a significantly lower cytogenic response than patients treated with a higher dose [2, 4]. Early trials showed no significant positive effect of a starting dose 400 mg/day in most patients if adverse effects are considered. Therefore, it was concluded that a 400-mg/day dose would be optimal in most patients [5]. However, in patients with an unsatisfactory response to the 400-mg/day dose, dose escalation to 600 mg/day or 800 mg/day can be effective without resulting in greater adverse effects. At a dose 800 mg/day, toxic effects are significantly greater without greater activity. In patients with CML, the overall survival rate after 60 months is estimated to be approximately 89% after treatment with imatinib. The progression-free survival rate at 60 months was approximately 83% (95% confidence interval, 79% 87%) in the same study [1]. In patients with GISTs, the progression-free survival duration after treatment with imatinib is estimated to be approximately 2 years. A European trial in GIST patients showed that the progression-free survival rate was signifi-
5 1394 Imatinib cantly higher in patients who started on 400 mg twice daily than in patients treated with 400 mg daily (56% versus 50%) [12]. PATIENT INSTRUCTIONS AND RECOMMENDATIONS FOR SUPPORTIVE CARE The tablets should be taken with a meal and a large glass of water to prevent gastrointestinal side effects. Tablets should be stored at room temperature. Liver function parameters (transaminases, alkaline phosphatase, bilirubin) should be monitored prior to start of therapy and as clinically indicated, initially monthly is advised. To monitor myelosuppression, it is advised that a CBC is performed weekly during the first month of treatment, biweekly during the second month, and once every 2 3 months thereafter. REFERENCES 1 Druker BJ, Guilhot F, O Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355: Capdeville R, Buchdunger E, Zimmerman J et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1: Desjardins A, Quinn JA, Vredenburgh JJ et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 2007;83: Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 2005;105: Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44: Titier K, Picard S, Ducint D et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005;27: Gardner ER, Burger H, van Schaik RH et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006;80: Gurney H, Wong M, Balleine RL et al. Imatinib disposition and ABCB1 (MDR-1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007;82: Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16: Villuendas R, Steegmann JL, Pollàn M et al. Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach. Leukemia 2006;20: Heinrich MC, Corless CL, Blanke CD et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24: Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364: Massagué J. G1 cell-cycle control and cancer. Nature 2004;432:
Gleevec. Gleevec (imatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.74 Subject: Gleevec Page: 1 of 6 Last Review Date: June 24, 2016 Gleevec Description Gleevec (imatinib)
More informationSTI571: Targeting BCR-ABL as Therapy for CML
STI571: Targeting BCR-ABL as Therapy for CML MICHAEL J. MAURO, BRIAN J. DRUKER Leukemia Program, Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland, Oregon, USA Key
More informationCML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL
1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor
More informationIt is also an option for those with Ph+ve CML who initially present in accelerated phase or with blast crisis 1.
Imatinib (Glivec ) Indications 1 Imatinib is recommended as first line treatment for people with Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase 1. It is also an
More informationImatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience
ORIGINAL ARTICLE Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience PC Bee, MMed*, G G Gan, MRCP*, A Teh, FRCP**, A R Haris, MRCP* *Department of Medicine, Faculty of Medicine,
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationIMATINIB MESYLATE (Gleevec or Glivec, Novartis,
Imatinib Treatment: Specific Issues Related to Safety, Fertility, and Pregnancy Martee L. Hensley and John M. Ford Imatinib (Gleevec) (formerly STI571) has demonstrated high levels of efficacy in chronic
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph C l i n i c a l A d v a n c e s i n H e m a t o l o g y & O n c o l o g y N o v e m b e r 2 0 0 9 Drug Plasma Monitoring in CML and GIST: A Case-based Discussion Faculty Merrill
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1037-6 Program Prior Authorization/Notification Medication Gleevec (imatinib mesylate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationscreening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib
Table S1. Study inclusion and exclusion criteria Inclusion criteria Aged 18 years Signed and dated informed consent form prior to protocol-specific screening procedures Cytogenetic- or PCR-based diagnosis
More informationImatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
ORIGINAL ARTICLE Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia Bahoush Gr, 1 Alebouyeh M, 2 Vossough P 1 1 Pediatric Hematology-Oncology Department, Ali-Asghar Children's Hospital,
More informationImatinib Therapy - GIST
INDICATIONS FOR USE: Imatinib Therapy - GIST Regimen Code INDICATION ICD10 Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationFrontiers in Cancer Therapy. John Glod, M.D., Ph.D.
Frontiers in Cancer Therapy John Glod, M.D., Ph.D. September 15, 2017 Objectives The Past: Alkylating agents The Present: Tyrosine Kinase Inhibitors The Future: Gene Expression, Metabolic cancers, CAR
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 March 2007 SPRYCEL 20 mg, film-coated tablet, blister (377 637-9) SPRYCEL 20 mg, film-coated tablet, bottle (377
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationGLEEVEC (imatinib mesylate) oral tablet IMATINIB MESYLATE oral tablet
IMATINIB MESYLATE oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationNCCP Chemotherapy Protocol. Bosutinib Monotherapy
Bosutinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous
More informationBCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib
BCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib Protocol Code Tumour Group Contact Physician ULKCMLP Leukemia Dr. Donna Forrest ELIGIBILITY:
More informationIntroduction to Cancer
Introduction to Cancer Clonal Evolution Theory of Tumor Development,2,2,,2,2,,2, Numbers represent sequential mutations to cellular genes Oncogenes and Tumor Suppresser Genes On Oncogenes Tumor Suppresser
More informationTalpaz M. et al. Dasatinib in Imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med (2006) 354;24:
References Sprycel Talpaz M. et al. Dasatinib in Imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med (2006) 354;24:2531-2541. National Comprehensive Cancer Network. Clinical Practice
More informationNOVARTIS v BRISTOL-MYERS SQUIBB
CASE AUTH/2016/7/07 NOVARTIS v BRISTOL-MYERS SQUIBB Sprycel leavepiece Novartis complained about a Sprycel (dasatinib) leavepiece issued by Bristol-Myers Squibb. Sprycel was indicated for use in patients
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations Summary Date prepared: May 2012 Imatinib was the first
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationGLEEVEC (imatinib mesylate) PATIENT RESOURCES
Talking with your doctor about Ph+ CML and its treatment When you have Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), it s important to take an active role in your care. You will
More informationChronic myeloid leukemia (CML) is a rare
Imatinib mesylate, a new drug for chronic myeloid leukemia in pediatric patients Vasantha Thavaraj, Rachna Seth New Delhi, India 110 Background: Imatinib mesylate (IM) is the greatest drug discovered in
More informationGLIVEC NAME OF THE MEDICINE DESCRIPTION. (imatinib)
GLIVEC (imatinib) NAME OF THE MEDICINE Active ingredient: Chemical name: imatinib as the mesylate salt. 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)- 2-pyrimidinyl]amino]-phenyl]benzamide
More informationClinical Policy: Imatinib (Gleevec) Reference Number: CP.PHAR.65 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Gleevec) Reference Number: CP.PHAR.65 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationSee 17 for PATIENT COUNSELING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GLEEVEC safely and effectively. See full prescribing information for GLEEVEC. GLEEVEC (imatinib mesylate)
More informationNCCP Chemotherapy Protocol. Ponatinib Therapy
INDICATIONS FOR USE: INDICATION Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant
More informationAn update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia
Singapore Med J 2012; 53(1) : 57 An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia Bee PC 1, MD, MMed, Gan GG 1, MBBS, FRCP, Tai YT 1, MBBS,
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationTKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients. Moustafa Sameer Hematology Medical Advsior,Novartis oncology
TKIs ( Tyrosine Kinase Inhibitors ) Mechanism of action and toxicity in CML Patients Moustafa Sameer Hematology Medical Advsior,Novartis oncology Introduction In people with chronic myeloid leukemia, A
More informationGLEEVEC (imatinib mesylate) Capsules FACT SHEET
Health Canada Santé Canada GLEEVEC (imatinib mesylate) Capsules FACT SHEET CONDITIONAL APPROVAL OF GLEEVEC This fact sheet notifies the Canadian public that Health Canada has issued a conditional marketing
More informationClinical Pharmacokinetics of Tyrosine Kinase Inhibitors
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors 2 Nielka P. van Erp, Hans Gelderblom, Henk-Jan Guchelaar Cancer Treatment Reviews 2009 (in press) Introduction Summary In the recent years, eight
More informationThe New England Journal of Medicine
ACTIVITY OF A SPECIFIC INHIBITOR OF THE BCR-ABL TYROSINE KINASE IN THE BLAST CRISIS OF CHRONIC MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA WITH THE PHILADELPHIA CHROMOSOME BRIAN J. DRUKER, M.D.,
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationLapatinib and Capecitabine Therapy
Lapatinib and Capecitabine Therapy This protocol should be read in conjunction with NCCP protocol 00216 Capecitabine Monotherapy. INDICATIONS FOR USE: INDICATION Treatment of adult patients with breast
More informationADVERSE REACTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Tyronib safely and effectively. See full prescribing information for Tyronib. TYRONIB (imatinib mesylate)
More informationOMONDI OGUDE MEDICAL ONCOLOGY
OMONDI OGUDE MEDICAL ONCOLOGY Personalized medicine (Targeted therapy) In recent years there s been a move from conventional cytotoxic therapy to more targeted therapy Mostly due to the rapid pace of
More informationHematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients
ORIGINAL ALBANIAN MEDICAL RESEARCH JOURNAL Hematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients Dorina Roko 1, Anila Babameto-Laku
More informationRole of pharmacogenetics in personalised imatinib dosing
Review Article Role of pharmacogenetics in personalised imatinib dosing Daniel T. Barratt 1,2, Andrew A. Somogyi 1,2,3 1 Discipline of Pharmacology, Adelaide Medical School, 2 Centre for Personalised Cancer
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationReference No: Author(s) NICaN Drugs and Therapeutics Committee. Approval date: 12/05/16. January Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Gastro- Intestinal Stromal Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationDeposited on: 24 November 2011
Iqbal, Z., Elliott, M., Watson, D.G., Holyoake, T.L. and Jorgensen, H.G. (2011) Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction
More informationBOSULIF (bosutinib) oral tablet
BOSULIF (bosutinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationIntroduction. Jose Francis 1 Biswajit Dubashi. Adithan Chandrasekaran 3
Med Oncol (2015)32:213 DOI 10.1007/s12032-015-0665-0 ORIGINAL PAPER Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationTREATMENT INTENT Disease modification- see European LeukemiaNet (ELN) 2013 guidelines for treatment goals.
BOSUTINIB INDICATION Licensed / NICE TA401 (BLUETEQ required) The treatment of adult patients with chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML)
More informationThe Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon
The Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon Imatinib revolutionized the treatment of chronic myelogenous leukemia (CML), improving the prognosis to such an extent that the
More informationStratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications
Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Kinga Malottki, Mousumi Biswas, Jon Deeks, Richard Riley, Charles Craddock, Lucinda Billingham
More informationOriginal Article. Keywords: Gastrointestinal stromal tumors (GIST); KIT; tyrosine kinase inhibitors (TKIs); immunohistochemical staining
Original Article Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico Abdel Karim Dip Borunda,
More informationMontpellier and Nimes University Hospital. 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs Madrid, September the 13th and 14th
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer Litaty MBATCHI, Matthieu GASSIOT,
More informationShould nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)?
Should nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)? http://test.metromomsblog.org/wp-content/uploads/2010/02/tortoise-and-the-hare.jpg D. Van
More informationimatinib imatinib A - Drug Name back to top B - Mechanism of Action and Pharmacokinetics
Drug Monograph Drug Name Mechanism of Action and Pharmacokinetics Indications and Status Adverse ffects Dosing Administration Guidelines Special Precautions Interactions Recommended Clinical Monitoring
More informationBC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib
BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid
More informationOncologist. The. Sarcomas. Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors
The Oncologist Sarcomas Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors TAE WON KIM, a MIN-HEE RYU, a HEUNGNAM LEE, b SUN JIN SYM, b JAE-LYUN
More informationNovel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)
Critical Reviews in Oncology/Hematology 57 (2006) 145 164 Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML) Contents Christoph Walz a, Martin Sattler a,b,
More informationKey Words. Imatinib Gleevec KIT CD117 Gastrointestinal stromal tumors
The Oncologist Regulatory Issues: FDA The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Approval
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationApproval based on the successful BFORE Phase 3 study conducted by Avillion under a collaborative development agreement with Pfizer
Avillion Announces US Approval of Pfizer s BOSULIF (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) Approval based on the successful BFORE Phase 3 study
More informationResponse to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation
DOI 10.1186/s13569-015-0036-9 CLINICAL SARCOMA RESEARCH CASE REPORT Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation Andrew S. Brohl 1*, Elizabeth G. Demicco
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationIntroduction. British Journal of Clinical Pharmacology
et al British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2004.02117.x In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite,
More information"Molecular Monitoring Strategies to Track Response to BCR-ABL Kinase Inhibitors in CML"
Association of Molecular Pathology USCAP Companion Meeting Sunday, February 12, 2006 7:00 PM Dan Jones, MD, PhD Associate Professor Medical Director, Molecular Diagnostic Laboratory Division of Pathology
More informationMP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Medical Policy BCBSA Ref. Policy: 2.04.85 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 8.01.30 Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
More informationCYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity Henrik Gréen, Karin Skoglund, Franz Rommel, Rajaa A. Mirghani, Kourosh Lotfi
More informationRelationship between CYP3A4 phenotype and sunitinib exposure in cancer patients
Relationship between CYP3A4 phenotype and sunitinib exposure in cancer patients 6 Nielka P. van Erp, Sharyn D. Baker, Alex Sparreboom, Zhaoyuan Chen, Jan den Hartigh, Jacqueline M.C. König-Quartel, Bart
More informationImatinib mesylate (Gleevec [STI-571]; Novartis Pharmaceuticals. Imatinib Mesylate Causes Hypopigmentation in the Skin
2483 Imatinib Mesylate Causes Hypopigmentation in the Skin Anne S. Tsao, M.D. 1 Hagop Kantarjian, M.D. 2 Jorge Cortes, M.D. 2 Susan O Brien, M.D. 2 Moshe Talpaz, M.D. 3 1 Medical Oncology Fellowship Program,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GLIVEC 50 mg capsules, hard 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 50 mg imatinib (as mesilate). For
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationLoss of Response to Imatinib: Mechanisms and Management
Loss of Response to Imatinib: Mechanisms and Management Neil P. Shah The treatment of chronic myeloid leukemia (CML) has been revolutionized by the small molecule BCR-ABLselective kinase inhibitor imatinib.
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationAxitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.
Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationManaging Relapse of CML Using Therapeutic Imatinib Plasma Level
H&0 CLINICAL CASE STUDIES Managing Relapse of CML Using Therapeutic Imatinib Plasma Level Adedayo A. Onitilo, MD, MSCR, FACP 1 Jessica M. Engel, MSN, FNP-BC 2 Department of Hematology/Oncology, 1 Marshfield
More informationWelcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
More informationClinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST)
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) Michael Heinrich 1, Robin Jones 2, Margaret von Mehren 3, Patrick
More informationSpecial pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Gefitinib SYNONYM(S): ZD1839 COMMON TRADE NAME(S): IRESSA CLASSIFICATION: epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Special pediatric considerations are noted when applicable,
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationPharmacogenetics and Pharmacokinetics
Chapter 2 Pharmacogenetics and Pharmacokinetics Mauro Saivezzo/ShutterStock, Inc. L earning O bjectives Upon completion of this chapter, the student will be able to: 1. Recognize the influence of genetic
More informationSubject: Dasatinib (Sprycel ) Tablets
09-J1000-43 Original Effective Date: 01/01/12 Reviewed: 01/10/18 Revised: 02/15/18 Subject: Dasatinib (Sprycel ) Tablets THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationAn Initiative to Equip Health-System Pharmacists to Select and Manage Drug Therapy for the Disease
An Initiative to Equip Health-System Pharmacists to Select and Manage Drug Therapy for the Disease What Health-System Pharmacists Should Know About CML Chronic myelogenous leukemia (CML, also known as
More informationWHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION
PHARMACOKINETICS I Absorption & Distribution LEARNING OUTCOMES By the end of the lecture students will be able to.. Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/08/21) Define pharmacokinetics,
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationWhy do patients take herbs and nutritional supplements?
Why do patients take herbs and nutritional supplements? Dissatisfaction with conventional medicine > Relieve cancer-related symptoms > Treat adverse effects of anticancer drugs > Treat cancer > Promote
More informationDasatinib (SPIRIT 2 Trial)
Dasatinib (SPIRIT 2 Trial) SPIRIT2 - STI571 Prospective International RandomIsed Trial 2 - A phase III, prospective randomised comparison of imatinib (STI571, Glivec or licensed generic) 400mg daily versus
More informationMolecular Oncology, oncology parameters see each test
Molecular Oncology, oncology parameters see each test DPD deficiency Dihydropyrimidine dehydrogenase deficiency (DPD deficiency) is an autosomal recessive metabolic disorder in which there is absent or
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationChronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors
17 (Supplement 10): x274 x279, 2006 doi:10.1093/annonc/mdl273 Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors A. Hochhaus III Medizinische Klinik, Medizinische Fakultät Mannheim
More information